Syngene International (SYNGENE) investor relations material

Executive summary

• FY 2027 is a transition year marked by strategic renewal, leadership change with Siddharth Mittal as CEO, and a focus on disciplined execution.

• The business is repositioning away from commoditized research services and over-dependence on a single biologics customer.

• Strategic priorities include strengthening the commercial engine, reaffirming CDMO as the primary growth driver, and investing in AI-led differentiated discovery capabilities.

• Signed MoU with Translational Health Science and Technology Institute (BRIC-THSTI) for clinical development and translational research.

• Recognized among the world's most sustainable companies for the second consecutive year.

Financial highlights

• Q1 FY27 consolidated revenue from operations was Rs. 7,360 million (INR 736 crore), down 16% year-over-year, mainly due to the absence of Zoetis offtake and client attrition in research services.

• Operating EBITDA margin dropped to 12% from 24% in Q1 FY26, impacted by lower revenues and a Rs. 501 million forex hedge loss.

• Profit after tax before exceptional items was Rs. 10 million; after exceptional termination benefits (Rs. 135 million), reported PAT was negative Rs. 90 million.

• Capital expenditure for the quarter was approximately Rs. 700 million, focused on facility and technology investments.

• Net cash balance at quarter-end was Rs. 1,541 crore.

Outlook and guidance

• Full-year guidance revised to a single-digit revenue decline in INR terms, with EBITDA margins expected in the mid-20s.

• H1 will see a significant impact, with better visibility and expected improvement in H2.

• Growth is expected to resume in FY 2028 as new commercial and clinical molecules ramp up utilization at key facilities.

• The company continues to monitor regulatory changes, especially regarding labor codes, and will adjust compliance and accounting as needed.